NJ State Employees Deferred Compensation Plan’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

NJ State Employees Deferred Compensation Plan’s Portfolio SIOX Stock Details SIOX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-2,625	Closed	-$314K	–	413
2017 Q1	$314K	Hold	2,625	–	–	0.06%	327
2016 Q4	$261K	Hold	2,625	–	–	0.05%	328
2016 Q3	$294K	Sell	2,625 -3,750	-59%	-$450K	0.06%	312
2016 Q2	$655K	Hold	6,375	–	–	0.14%	226
2016 Q1	$640K	Hold	6,375	–	–	0.14%	237
2015 Q4	$920K	Hold	6,375	–	–	0.19%	182
2015 Q3	$659K	Buy	+6,375	New	+$748K	0.14%	227

Other funds holding SIOX

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

NJ State Employees Deferred Compensation Plan's SIOX Position: Q2 2017 in Review

NJ State Employees Deferred Compensation Plan sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q2 2017, closing a stake of 2,625 shares — an estimated $314K sold.

NJ State Employees Deferred Compensation Plan first reported a position in SIOX in Q3 2015 and held it in 7 quarters. The position peaked at $920K in Q4 2015. 113 funds tracked by Wall St. Rank hold SIOX as of Q2 2017.

NJ State Employees Deferred Compensation Plan reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q2 2017 after selling out during the quarter.
NJ State Employees Deferred Compensation Plan sold 2,625 Sio Gene Therapies Inc. Common Stock shares in Q2 2017, an estimated $314K.
NJ State Employees Deferred Compensation Plan first reported a position in Sio Gene Therapies Inc. Common Stock in Q3 2015 and held it in 7 quarters.
NJ State Employees Deferred Compensation Plan's Sio Gene Therapies Inc. Common Stock position peaked at $920K in Q4 2015.
113 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q2 2017.

Based on NJ State Employees Deferred Compensation Plan's 13F filing for Q2 2017, filed 28 Jul 2017.